1 / 9

Human Insulin market

Human Insulin market

Mayuri24
Download Presentation

Human Insulin market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Human Insulin Market Trends, Size, Share, Demands, Overview, Growth, Revenue and Forecast to 2030 sales@delvens.comwww.delvens.com

  2. Sternal Closure Systems Market – Trends Forecast Till 2030 Human Insulin Market, by product type (traditional human insulins, basal or long-acting insulins, bolus or fast-acting insulins, insulin combinations, and biosimilar insulins), Drugs (Biologics, Biosimilars), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes) Application (Type 1 Diabetes, Type 2 Diabetes) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America). Request For Free Sample Report: https://www.delvens.com/get-free-sample/human-insulin-market sales@delvens.com www.delvens.com

  3. Market Overview Human Insulin or Insulin is a hormone produced in the human pancreas that regulates the amount of glucose (sugar) in the bloodstream and the metabolism of fats, proteins and carbohydrates in the human body. Insulin is available in different strengths; the most common is U-100, which is used as a dietary and exercise supplement to improve glucose balance in children and adults. The growth of the global market is attributed to key factors such as increasing demand for human insulin analogues and affordable reimbursements. Technological innovations in human insulin delivery devices are also boosting the market. For example, in August 2020, the US FDA approved the MiniMed 770G, an innovative diabetes management device. This device automatically monitors glucose levels and delivers the correct basal insulin doses to pediatric patients with type 1 diabetes with minimal client (caregiver) input. Purchase this Report: https://www.delvens.com/checkout/human-insulin-market sales@delvens.com www.delvens.com

  4. Market Overview The growth of the global market is attributed to key factors such as increasing demand for human insulin analogues and affordable reimbursements. Technological innovations in human insulin delivery devices are also boosting the market. For example, in August 2020, the US FDA approved the MiniMed 770G, an innovative diabetes management device. This device automatically monitors glucose levels and delivers the correct basal insulin doses to pediatric patients with type 1 diabetes with minimal client (caregiver) input. The COVID-19 pandemic has significantly affected the human insulin drug market. Patients with type 1 diabetes were more affected during Covid-19. Diabetics have a weak immune system, so in case of COVID-19, the immune system weakens very quickly. Diabetics are more likely to develop serious complications than the general population. In the midst of the pandemic, there have been delays and disruptions in the supply of medicines due to strategies designed to contain the spread of SARS-CoV-2. In addition, hospitals reported a decrease in insulin prescriptions. However, in several countries, the impact of COVID-19 decreased after the second quarter of 2021, helping the market to pull back. sales@delvens.com www.delvens.com

  5. Key Findings The Human Insulin market is segmented into various segments such product type, brands, delivery devices, application, drugs and region: By product, the human insulin market is divided into two main segments: drugs and dosing devices. The human insulin drug segment is expected to account for the largest share of the global market by product in 2022. The application segment is further bifurcated into type-1 and type-2 diabetes. The largest segment by application is type 1 diabetes mellitus, due to the high insulin dependency of these patients. It is a more severe condition than type 2 diabetes. sales@delvens.com www.delvens.com

  6. Key Findings By product type, the human insulin device market is divided into three segments: pens, pen needles and syringes. The pen segment is expected to account for the largest market share in 2022; it will be the fastest growing segment in the next five years The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. Inquire Before Buying: https://www.delvens.com/Inquire-before-buying/human-insulin-market sales@delvens.com www.delvens.com

  7. Competitive Landscape • Novo Nordisk A/S • Eli Lilly and Company • Sanofi • Pfizer Inc. • Biocon Ltd • Wockhardt • Boehringer Ingelheim International GmbH • Julphar • United Laboratories International Holdings Limited • TonghuaDongbao Pharmaceutical Co. Ltd. • Exir • Sedico • Bristol-Myers Squibb Company • GlaxoSmithKline Plc • Oramed • Adocia • Merck & co. Inc sales@delvens.com www.delvens.com

  8. Recent Developments November 2022: The U.S. Food and Drug Administration approved Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type-1 diabetics and pediatric patients 8 years of age and older who were stage 2 type-1 diabetics. May 2022: The FDA approved Lilly’s new medication Mounjaro (also known as tirzepatide) for type-2 diabetes management in addition to diet and exercise. This first-in-class medication showed improvement in glucose levels and also dramatically improved weight in clinical trials. sales@delvens.com www.delvens.com

  9. Contact Information About Us: Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally. Contact Us: +44-20-3290-6466 +1 214-377-1144 sales@delvens.com sales@delvens.com www.delvens.com

More Related